A team of researchers have been working on a promising emerging technology for diagnosing COVID and possibly other infectious diseases. The Quenchbody fluorescent immunosensor can detect COVID with exceptional speed and sensitivity, and also offers a simple way to greatly enhance the immunosensor’s performance using a crowding agent.
Impetus for the New Test
The fast spread of COVID throughout the world signified a greater need to establish better methods to diagnose infectious diseases quickly and efficiently. During the early months of the pandemic, polymerase chain reaction (PCR) tests were one of the most widely used techniques to detect COVID-19. However, these viral RNA-based techniques require expensive equipment and reaction times longer than an hour, which renders them less than ideal for point-of-care testing.
The limitations of PCR fueled the development of various immunoassay methods, which use specially engineered antibodies to detect SARS-CoV-2 antigens with high sensitivity in little time. Today, scientists are still improving immunoassay technology to make available tools more convenient, sensitive, and cost-effective.
Thus, the team of researchers led by Professor Hiroshi Ueda from Tokyo Institute of Technology (Tokyo Tech), Japan, helped to develop the new Quenchbody fluorescent immunosensor. Their latest paper, published in Analyst, details the new immunosensors.
But what exactly are Quenchbodies?
A Quenchbody is a molecular sensor originally developed by Professor Ueda and colleagues using antibody fragments and fluorescent tags. The antibody fragment, which can be an antigen-binding region (or ‘Fab’), targets a specific viral molecule (antigen). Meanwhile, the fluorescent tags are small fluorescent dye molecules attached by a peptide linker to the Quenchbody, near the antigen-binding region. When the antigen is absent, the fluorescent tags are attracted to the Fab and intrinsic amino acids (mainly tryptophan) interact with the dyes and quench the fluorescence.
However, when the antigen appears, it replaces the fluorescent tag at the Fab, causing it to move away and recover its fluorescence. Thus, in a Quenchbody test, an increase in fluorescence indicates the detection of the target antigen.
In this study, the research team developed a double-tagged Quenchbody targeting the nucleocapsid protein (N protein) of SARS-CoV-2. To take things one step further, they also tested whether various commercially available compounds could improve the immunosensor’s sensitivity and detection time. In particular, adding polyethylene glycol 6000 (PEG6000) at the right concentration as a crowding agent increased performance quite significantly.
“The enhanced limit of detection against the N protein was lower than 0.3 nM within 5 minutes of incubation, which is an order of magnitude more sensitive than without adding a crowding agent,” says Professor Ueda.
To further validate their approach, the team tested their immunosensor on leftover clinical samples from COVID positive patients. After careful analysis of the results, they concluded that their newly developed Quenchbody could measure N protein more easily and quantitatively than a commercial lateral flow antigen test.
“Our work shows the feasibility of using Quenchbody immunosensors as rapid and cost-efficient tools for the diagnosis and high-throughput analysis of swab samples in large-scale monitoring and epidemiological studies of COVID-19, as well as other emerging infectious diseases,” says Ueda.
Photo: Tokyo Tech, Analyst